GSK (BUE:GSK) Cyclically Adjusted FCF per Share: ARS1,543.38 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:GSK GSK PLC BUE:GSK
65 GF Score
Price ARS20,090.00
GF Value ARS16,957.00
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK Cyclically Adjusted FCF per Share?

GSK BUE:GSK +0.70% 65 Cyclically Adjusted FCF per Share is ARS1,543.38 as of Mar. 2026. GuruFocus rates BUE:GSK with a GF Score™ of 65/100 and a GF Value™ of ARS16,957.00 (Modestly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

GSK's adjusted free cash flow per share for the three months ended in Mar. 2026 was ARS159.708. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ARS1,543.38 for the trailing ten years ended in Mar. 2026.

During the past 12 months, GSK's average Cyclically Adjusted FCF Growth Rate was 10.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 3.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 4.50% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of GSK was 83.40% per year. The lowest was -0.60% per year. And the median was 4.50% per year.

As of today (2026-07-24), GSK's current stock price is ARS20090.00. GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ARS1,543.38. GSK's Cyclically Adjusted Price-to-FCF of today is 13.02.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of GSK was 16.26. The lowest was 9.05. And the median was 12.31.


GSK  (BUE:GSK) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

GSK's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=20090.00/1543.38
=13.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of GSK was 16.26. The lowest was 9.05. And the median was 12.31.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


GSK Cyclically Adjusted FCF per Share Related Terms


GSK Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for GSK's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Cyclically Adjusted FCF per Share Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 214.81 288.75 857.10 1,038.69 1,577.56

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,235.94 1,254.17 1,620.86 1,577.56 1,543.38

BUE:GSK vs LLY, JNJ, ABBV: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted Price-to-FCF falls into.


BUE:GSK
65GF Score
GSK PLC BUE:GSK
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=159.708/140.8000*140.8000
=159.708

Current CPI (Mar. 2026) = 140.8000.

GSK Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 1.939 101.000 2.703
201609 3.179 101.500 4.410
201612 5.565 102.200 7.667
201703 1.761 102.700 2.414
201706 1.069 103.500 1.454
201709 4.146 104.300 5.597
201712 7.051 105.000 9.455
201803 1.807 105.100 2.421
201806 4.124 105.900 5.483
201809 9.953 106.600 13.146
201812 20.844 107.100 27.403
201903 2.321 107.000 3.054
201906 5.347 107.900 6.977
201909 17.763 108.400 23.072
201912 26.005 108.500 33.747
202003 5.951 108.600 7.715
202006 25.139 108.800 32.533
202009 2.540 109.200 3.275
202012 44.745 109.400 57.588
202103 -0.357 109.700 -0.458
202106 12.141 111.400 15.345
202109 22.579 112.400 28.284
202112 53.242 114.700 65.357
202203 34.305 116.500 41.460
202206 17.182 120.500 20.077
202209 16.187 122.300 18.636
202212 28.808 125.300 32.372
202303 -13.968 126.800 -15.510
202306 28.578 129.400 31.096
202309 90.318 130.100 97.746
202312 133.817 130.500 144.379
202403 51.405 131.600 54.999
202406 92.732 133.000 98.170
202409 199.172 133.500 210.063
202412 183.375 135.100 191.112
202503 116.024 136.100 120.031
202506 286.709 138.400 291.681
202509 300.416 138.900 304.525
202512 298.296 139.900 300.215
202603 159.708 140.800 159.708

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ARS1,543.38 mean?
GSK (BUE:GSK) has a Cyclically Adjusted FCF per Share of ARS1,543.38 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on GSK and its competitors.
Is GSK's Cyclically Adjusted FCF per Share too high?
GSK's current Cyclically Adjusted FCF per Share is ARS1,543.38. Overall, GSK has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Cyclically Adjusted FCF per Share compare to LLY and JNJ?
GSK's Cyclically Adjusted FCF per Share of ARS1,543.38 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on GSK and its competitors. GSK's current Cyclically Adjusted FCF per Share is ARS1,543.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (BUE:GSK) is currently considered Modestly Overvalued. The stock's GF Value™ is ARS16,957.00, compared to a current price of ARS20,090.00 — trading 18.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ARS1,543.38. GSK's overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For GSK (BUE:GSK), the current Cyclically Adjusted FCF per Share is ARS1,543.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (BUE:GSK) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of ARS20,090.00 is trading 18.5% above its estimated GF Value™ of ARS16,957.00. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for BUE:GSK:

  • Cyclically Adjusted FCF per Share: ARS1,543.38
  • GF Value™: ARS16,957.00 vs. price of ARS20,090.00 (18.5% above fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the BUE:GSK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
65GF Score

Get the complete analysis for BUE:GSK

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS20,090.00
Price
ARS16,957.00
GF Value